Autoimmunity

Frazier Life Sciences Adds Highly Experienced T Cell Immunologist to Team

Retrieved on: 
Wednesday, February 1, 2023
Professional Services, Oncology, Health, Finance, Pharmaceutical, Biotechnology, CAR, The W. Alton Jones Cell Science Center, Senior advisor, Berkeley, Genentech, Harvard University, Leukemia, Acquisition, Canadian Aviation Regulations, University, Doctor of Philosophy, Research, Cell, Therapy, Sanofi, Cancer immunology, UCSF, Autoimmunity, Pharmaceutical industry, Vaccine, Physiology, Science, Immunology, Immunity

Frazier Life Sciences announced the addition of Bryan A. Irving, Ph.D. as a Senior Advisor.

Key Points: 
  • Frazier Life Sciences announced the addition of Bryan A. Irving, Ph.D. as a Senior Advisor.
  • He has 30 years of experience as a T cell immunologist, including 23 years in the biotech industry focused on discovering and progressing immune drug candidates into the clinic for both autoimmune and oncology indications.
  • His work has been published in top-tier journals including Cell, Science, Cancer Cell, Nature Immunology, and Immunity, and he is an inventor on patents that include the single-chain CARs and atezolizumab.
  • “He is a highly experienced T cell immunologist, and we believe his insights will help us better understand and approach the increasingly complex strategies being pursued in immuno-oncology.”

Drug Inflation Rate Continues Upward Trend at 3.78%: Vizient Pharmacy Market Outlook

Retrieved on: 
Thursday, January 26, 2023
Oncology, Medical Supplies, Health, Hospitals, Practice Management, Pharmaceutical, Ustekinumab, Pharmacy, Outlook, Melanoma, Patient, Asthma, Atopic dermatitis, Daratumumab, Dupilumab, Forecasting, Multiple myeloma, COVID-19, Adalimumab, Autoimmunity, Generic drug, Pharmaceutical industry, Vizient, Inc.

Vizient, Inc. released its Winter 2023 Pharmacy Market Outlook, forecasting a 3.78% overall drug price inflation rate for the calendar year beginning, July 1, 2023.

Key Points: 
  • Vizient, Inc. released its Winter 2023 Pharmacy Market Outlook, forecasting a 3.78% overall drug price inflation rate for the calendar year beginning, July 1, 2023.
  • The rate reflects a moderate rise relative to recent years but also a growing upward trend led by an increase in prices and utilization.
  • Drug spend for remdesivir (Veklury®), which soared to the top of total Vizient member spend in the Winter 2022 Outlook, continues its decline from No.
  • Vizient continues to advocate for greater transparency throughout the pharmaceutical supply chain to bolster supply assurance and end drug shortages.

Aqilion announces pre-clinical licensing and strategic research collaboration agreement with Merck

Retrieved on: 
Thursday, February 16, 2023
Alnitak, Pharmacology, EUR, DSM-IV codes, Merck, Drug discovery, Therapy, Inflammation, Autoimmunity, Pharmaceutical industry

HELSINGBORG, Sweden, Feb. 16, 2023 /PRNewswire/ -- AQILION AB ("Aqilion") today announced an exclusive license and strategic research collaboration with Merck to discover, develop and commercialize small molecule inhibitors of the transforming growth factor-β-activated kinase 1 (TAK1) protein.

Key Points: 
  • HELSINGBORG, Sweden, Feb. 16, 2023 /PRNewswire/ -- AQILION AB ("Aqilion") today announced an exclusive license and strategic research collaboration with Merck to discover, develop and commercialize small molecule inhibitors of the transforming growth factor-β-activated kinase 1 (TAK1) protein.
  • Merck will make an upfront cash payment of EUR 10 million to Aqilion.
  • In addition, Aqilion is eligible to receive potential development and commercialization milestones up to over EUR 950 million and tiered royalties on worldwide net sales.
  • During the collaboration, Aqilion will be responsible for the design and synthesis of novel small molecule TAK1 inhibitors while Merck will lead preclinical pharmacology and biology studies.

Aqilion announces pre-clinical licensing and strategic research collaboration agreement with Merck

Retrieved on: 
Thursday, February 16, 2023
Alnitak, Pharmacology, EUR, DSM-IV codes, Merck, Drug discovery, Therapy, Inflammation, Autoimmunity, Pharmaceutical industry

HELSINGBORG, Sweden, Feb. 16, 2023 /PRNewswire/ -- AQILION AB ("Aqilion") today announced an exclusive license and strategic research collaboration with Merck to discover, develop and commercialize small molecule inhibitors of the transforming growth factor-β-activated kinase 1 (TAK1) protein.

Key Points: 
  • HELSINGBORG, Sweden, Feb. 16, 2023 /PRNewswire/ -- AQILION AB ("Aqilion") today announced an exclusive license and strategic research collaboration with Merck to discover, develop and commercialize small molecule inhibitors of the transforming growth factor-β-activated kinase 1 (TAK1) protein.
  • Merck will make an upfront cash payment of EUR 10 million to Aqilion.
  • In addition, Aqilion is eligible to receive potential development and commercialization milestones up to over EUR 950 million and tiered royalties on worldwide net sales.
  • During the collaboration, Aqilion will be responsible for the design and synthesis of novel small molecule TAK1 inhibitors while Merck will lead preclinical pharmacology and biology studies.

CerraCap Ventures invests in Predicta Med, an autoimmune disease detection and intervention recommendation company

Retrieved on: 
Friday, February 10, 2023
VCS, KSM, Deep learning, Ulcerative colitis, History of Stanford Medicine, Multiple sclerosis, Psoriatic arthritis, Entrepreneurship, Rheumatoid arthritis, Diagnosis, Immediate, Disease, Aircraft, Southern California, Patient, S&M, Health, Risk, Venture capital, Stanford University School of Medicine, Health care, Innovation, Research, Conditional sentence, EMR, Autoimmunity, Vaccine, Pharmaceutical industry

COSTA MESA, Calif., Feb. 10, 2023 /PRNewswire/ -- SoCal headquartered Venture Capital fund, CerraCap Ventures, has announced a strategic investment in Predicta Med, one of the world's leading early startups helping medical clinics and institutions identify and work-up immune-related diseases earlier.

Key Points: 
  • Predicta Med is building the world's first decision support platform for early detection and intervention recommendation of immune-related diseases.
  • These collaborations have enriched Predicta Med's data analytics platform with more than 8.5 million EMR and claims records.
  • Predicta Med's mission is to help improve the lives of millions of patients affected by more than 100 autoimmune and immune-related diseases known today.
  • Shlomit Steinberg-Koch, Co-Founder and CEO of Predicta Med, added, "We are excited to have CerraCap Ventures on board so early in our journey.

Thrive Health Infusion Centers Launch for Thyroid Eye Disease in Tandem with Thyroid Awareness Month

Retrieved on: 
Wednesday, January 25, 2023
Legal outsourcing, MD, Graves' ophthalmopathy, Hyperthyroidism, Thyroid disease, FDA, Grave, TED, Woman, Patient, Clinical trial, MSO, LOS, Doctor of Philosophy, Autoimmunity, Pharmaceutical industry

LOS ANGELES, Jan. 25, 2023 /PRNewswire-PRWeb/ -- Thrive Health Infusion Centers, founded by Raymond Douglas, MD, PhD, renowned board certified oculoplastic surgeon, with its flagship location in Beverly Hills, California, announces the opening of Long Beach, Newport Beach and San Diego, CA centers creating a leadership presence in the treatment of Thyroid Eye Disease in California. Thrive Health, the first-of-its-kind offering viable, FDA approved non-surgical treatment options as well as clinical trials for new advances in treatment and care for TED and other rare ophthalmic diseases, also opened a New York City flagship.

Key Points: 
  • Thyroid conditions are on the rise with an estimated 20 million Americans having some form of thyroid disease and 1 in 8 women developing a thyroid condition in their lifetime.
  • Thrive Health leverages cutting edge science and expertise in the growing category of medical biologics with leadership in clinical trials.
  • To meet the need of the growing patient population with the autoimmune thyroid condition, the integrated concierge and patient centric medical management treatment centers will announce additional centers in the coming months.
  • Beyond onsite infusion, patient planning and treatment protocols, oversight of benefits approvals, surgical offerings or referrals as needed, Thrive Health is unique in furthering concierge medical collaborations.

Enable Medicine Identifies Sex-Dependent Differences in Resistance to Common Treatment for Ulcerative Colitis

Retrieved on: 
Tuesday, January 24, 2023
Cloud, UC, TNF, TNF inhibitor, Participation bias, Colitis, Atlas, Stanford University, University of California, San Diego, IBD, Female, Cancer, Science Advances, Medicine, Patient, Risk, Infection, Ulcerative colitis, Autoimmunity, Pharmaceutical industry, Medical imaging

In the paper the researchers identified cellular signatures that indicate resistance to TNF inhibitor (TNFi) therapy, the front-line treatment for ulcerative colitis (UC).

Key Points: 
  • In the paper the researchers identified cellular signatures that indicate resistance to TNF inhibitor (TNFi) therapy, the front-line treatment for ulcerative colitis (UC).
  • Combined direct and indirect costs caused by ulcerative colitis are estimated at $45 billion per year in the United States and Europe.
  • The paper identifies sex-related differences in the frequency of specific cellular signatures in untreated patients.
  • Notably, this is the most comprehensive spatial atlas of ulcerative colitis released by researchers to date.

Revolo Biotherapeutics to Present Recently Generated Data at the 2023 AAAAI Annual Meeting Demonstrating Anti-inflammatory Effect of ‘1104 in Food Allergy

Retrieved on: 
Monday, February 6, 2023
Immune system, American Academy, Food allergy, Patient, AAAAI, Autoimmunity, Pharmaceutical industry, Vaccine

NEW ORLEANS and LONDON, Feb. 06, 2023 (GLOBE NEWSWIRE) -- Revolo Biotherapeutics (“Revolo” or the “Company”), a company developing therapies that reset the immune system to achieve superior long-term remission for patients with autoimmune and allergic diseases, today announced that recently generated preclinical data for ‘1104 in Food Allergy will be presented at the 2023 American Academy of Allergy Asthma and Immunology (AAAAI) Annual Meeting, which is being held February 24-27 in San Antonio, Texas.

Key Points: 
  • NEW ORLEANS and LONDON, Feb. 06, 2023 (GLOBE NEWSWIRE) -- Revolo Biotherapeutics (“Revolo” or the “Company”), a company developing therapies that reset the immune system to achieve superior long-term remission for patients with autoimmune and allergic diseases, today announced that recently generated preclinical data for ‘1104 in Food Allergy will be presented at the 2023 American Academy of Allergy Asthma and Immunology (AAAAI) Annual Meeting, which is being held February 24-27 in San Antonio, Texas.

Tonix Pharmaceuticals to Participate in BIO CEO & Investor Conference

Retrieved on: 
Friday, February 3, 2023
Prader–Willi syndrome, Long COVID, Psychiatry, IR, CNS, Disease, Failure, MDD, COVID-19, Security (finance), Smallpox, Cancer, Government, Infection, BIO, Therapy, Orphan drug, RPV, Fibromyalgia, Conference, SL, Central nervous system, Breakthrough therapy, Monkeypox, CD40L, FDA, Hydrogen chloride, Risk, Neurology, Autoimmunity, Degenerative disease, Research, Pain, Annual report, Pharmaceutical industry, CD154, Tonix Pharmaceuticals

CHATHAM, N.J., Feb. 03, 2023 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced that Seth Lederman, M.D., President and Chief Executive Officer of Tonix Pharmaceuticals, will participate virtually in the BIO CEO & Investor Conference, which is being held February 6-9, 2023.

Key Points: 
  • CHATHAM, N.J., Feb. 03, 2023 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced that Seth Lederman, M.D., President and Chief Executive Officer of Tonix Pharmaceuticals, will participate virtually in the BIO CEO & Investor Conference, which is being held February 6-9, 2023.
  • The Company’s pre-recorded presentation will be made available during the conference to registered conference participants through the BIO CEO & Investor Conference website at https://www.bio.org/events/bio-ceo-investor-conference/sessions.
  • Beginning February 9, 2023, the presentation will also be available under the IR Events tab of the Investors section of the Tonix website at www.tonixpharma.com .
  • Tonix is a clinical-stage biopharmaceutical company focused on discovering, licensing, acquiring and developing therapeutics to treat and prevent human disease and alleviate suffering.

Immunocore to present at upcoming investor conferences

Retrieved on: 
Wednesday, February 1, 2023
TCR, Cancer, Infection, Autoimmunity, Pharmaceutical industry, Phonograph record

(OXFORDSHIRE, England & CONSHOHOCKEN, Penn.

Key Points: 
  • (OXFORDSHIRE, England & CONSHOHOCKEN, Penn.
  • & ROCKVILLE, Md., US, 01 February 2023) Immunocore Holdings Plc (Nasdaq: IMCR), a commercial-stage biotechnology company pioneering the development of a novel class of T cell receptor (TCR) bispecific immunotherapies designed to treat a broad range of diseases, including cancer, autoimmune, and infectious diseases, today announced that management will present at the following investor conferences in February:
    The presentations will be webcast live and will be available in the ‘Investors’ section of Immunocore’s website at www.immunocore.com.
  • A replay of the presentations will be made available for a limited time.